Charles River Laboratories International, Inc. $CRL Shares Sold by State of Wyoming

Posted by Geri Gentry on Jul 30th, 2026

State of Wyoming lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 61.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,403 shares of the medical research company’s stock after selling 2,203 shares during the period. State of Wyoming’s holdings in Charles River Laboratories International were worth $242,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of CRL. Cardinal Capital Management boosted its stake in shares of Charles River Laboratories International by 0.6% during the 4th quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after buying an additional 62 shares during the last quarter. Asset Management One Co. Ltd. raised its holdings in Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 71 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Charles River Laboratories International by 1.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after acquiring an additional 80 shares in the last quarter. Advisory Services Network LLC boosted its stake in Charles River Laboratories International by 2.6% during the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after acquiring an additional 83 shares during the last quarter. Finally, Brown Miller Wealth Management LLC grew its holdings in Charles River Laboratories International by 7.0% during the 1st quarter. Brown Miller Wealth Management LLC now owns 1,278 shares of the medical research company’s stock worth $220,000 after acquiring an additional 84 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. The trade was a 70.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 2.0%

CRL stock opened at $235.61 on Thursday. The firm’s 50-day moving average is $203.64 and its two-hundred day moving average is $187.73. The company has a market capitalization of $11.35 billion, a price-to-earnings ratio of -62.66, a price-to-earnings-growth ratio of 2.68 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $242.73. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the business earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts forecast that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Mizuho lifted their price target on Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Finally, Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $220.75.

Read Our Latest Research Report on CRL

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.